Compare PKE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | FULC |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.2M | 467.8M |
| IPO Year | 1994 | 2019 |
| Metric | PKE | FULC |
|---|---|---|
| Price | $33.86 | $6.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 175.8K | ★ 569.9K |
| Earning Date | 05-15-2026 | 04-27-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $89.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.30 | $5.89 |
| 52 Week High | $35.86 | $15.74 |
| Indicator | PKE | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 38.86 |
| Support Level | $32.00 | $6.36 |
| Resistance Level | $35.58 | $7.09 |
| Average True Range (ATR) | 1.47 | 0.40 |
| MACD | -0.22 | -0.09 |
| Stochastic Oscillator | 61.25 | 28.00 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.